Comment: US FTC's Amgen-Horizon challenge could chill healthcare M&A, but has high hurdle with risky conglomerate theory
A US Federal Trade Commission lawsuit to block Amgen’s proposed acquisition of Horizon Therapeutics has potentially serious ramifications for dealmaking in the healthcare sector, but the agency took a bold risk...To view the full article, register now.
Already a subscriber? Click here to view full article